NCT02205359已完成不适用
AdaptResponse Clinical Trial
Medtronic Cardiac Rhythm and Heart Failure278 个研究点 分布在 1 个国家目标入组 3,797 人开始时间: 2014年8月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 3,797
- 试验地点
- 278
- 主要终点
- Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation
研究概览
简要总结
The purpose of this clinical study is to test the hypothesis that market released Cardiac Resynchronization Therapy (CRT) devices which contain the AdaptivCRT® (aCRT) algorithm have a superior outcome compared to standard CRT devices in CRT indicated patients with normal atrio-ventricular (AV) conduction and left bundle branch block (LBBB).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is willing to sign and date the study Patient Informed Consent Form.
- •Subject is indicated for a CRT device according to local guidelines.
- •Sinus Rhythm at time of enrollment
- •Complete Left Bundle Branch Block (LBBB) as documented on an ECG (within 30 days prior to enrollment). Strauss Criteria used for LBBB.
- •Intrinsic, normal AV conduction as documented on an ECG by a PR interval less than or equal to 200ms (within 30 days prior to enrollment).
- •Left ventricular ejection fraction less than or equal to 35% (documented within 180 days prior to enrollment).
- •NYHA class II, III or IV (documented within 30 days prior to enrollment) despite optimal medical therapy. Optimal medical therapy is defined as maximal tolerated dose of Beta-blockers and a therapeutic dose of ACE-I, ARB or Aldosterone Antagonist.
排除标准
- •Subject is less than 18 years of age (or has not reached minimum age per local law).
- •Subject is not expected to remain available for at least 2 years of follow-up visits.
- •Subject has permanent atrial arrhythmias for which pharmacological therapy and/or cardioversion have been unsuccessful or have not been attempted
- •Subject is, or previously has been, receiving cardiac resynchronization therapy.
- •Subject is currently enrolled or planning to participate in a potentially confounding drug or device trial during the course of this study. Co-enrollment in concurrent trials is only allowed when documented pre-approval is obtained from the Medtronic study manager.
- •Subject has unstable angina, or experienced an acute myocardial infarction (MI) or received coronary artery revascularization (CABG) or coronary angioplasty (PTCA) within 30 days prior to enrollment.
- •Subject has a mechanical tricuspid heart valve or is scheduled to undergo valve repair or valve replacement during the course of the study.
- •Subject is post heart transplant (subjects on the heart transplant list for the first time are not excluded).
- •Subject has a limited life expectancy due to non-cardiac causes that would not allow completion of the study.
- •Subject is pregnant (if required by local law, women of child-bearing potential must undergo a pregnancy test within seven days prior to device implant).
- •Subject meets any exclusion criteria required by local law.
结局指标
主要结局
Combined Endpoint of All-cause Mortality and Intervention for Heart Failure Decompensation
时间窗: from subject randomization until the first occurrence of death or intervention for heart failure decompensation, median follow-up 4.9 years (max. follow-up 8.1 years)
The first occurrence of death or intervention for heart failure decompensation (defined as an event requiring invasive intervention or inpatient hospitalization).
次要结局
- All-cause Mortality(from subject randomization until the occurrence of death, median follow-up 4.9 years (max. follow-up 8.1 years))
- Atrial Fibrillation(from subject randomization until the first occurrence of atrial fibrillation lasting >6 hours in one day, median follow-up 4.9 years (max. follow-up 8.1 years))
- Change in Quality of Life Measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ)(from baseline to 24M follow up)
- Change in Quality of Life Measured by the EQ-5D(from baseline to 24M follow up)
- All-cause Re-admissions Within 30 Days After a Heart Failure Admission Per 100 Patient Years(from subject randomization until study exit, median follow-up 4.9 years (max. follow-up 8.1 years))
- Clinical Composite Score(CCS at 6 month post randomization)
- Percent of Patients With Interventions for Heart Failure Decompensation(from subject randomization until the first occurrence of intervention for heart failure decompensation, median follow-up 4.9 years (max. follow-up 8.1 years))
研究者
研究点 (278)
Loading locations...
相似试验
招募中
不适用
Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy AssessmentCardiac Resynchronization TherapyLeft Bundle-Branch BlockChronic Heart FailureNCT05327062XSpline S.p.A.150
已完成
不适用
Multicenter Automatic Defibrillator Implantation Trial - Chemotherapy-Induced CardiomyopathyCardiomyopathyNCT02164721University of Rochester30
招募中
不适用
Optimal Pacing Rate for Cardiac Resynchronization TherapyAtrial Fibrillation, PersistentNCT06445439Medstar Health Research Institute60
终止
3 期
MADIT ASIA Cardiac Resynchronization TrialHeart Failure, SystolicCongestive Heart FailureLeft Bundle Branch BlockNCT01872234Boston Scientific Corporation1
终止
不适用
Biventricular Versus Right Ventricular PacingHeart FailureNCT06298669Indiana University1